RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS

Clinical trials for RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New combo shows promise for Hard-to-Treat lymphoma

Disease control Completed

This study tested a combination of two drugs, Imprime PGG and Rituximab, in 25 people with a type of blood cancer called indolent non-Hodgkin lymphoma that had come back or not responded to prior treatment. The goal was to see how many patients had their tumors shrink or disappea…

Matched conditions: RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Apr 26, 2026 20:02 UTC

RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS

Get alerted when new RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS trials appear

New combo shows promise for Hard-to-Treat lymphoma